Analysts Set Expectations for KPTI Q1 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Leerink Partnrs issued their Q1 2025 earnings estimates for Karyopharm Therapeutics in a research report issued on Wednesday, February 19th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of ($0.26) per share for the quarter. The consensus estimate for Karyopharm Therapeutics' current full-year earnings is ($0.71) per share. Leerink Partnrs also issued estimates for Karyopharm Therapeutics' Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.39) EPS.

Several other research firms have also issued reports on KPTI. Royal Bank of Canada restated an "outperform" rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. HC Wainwright restated a "buy" rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. StockNews.com downgraded shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 22nd. Finally, Piper Sandler boosted their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $5.00.

Karyopharm Therapeutics Price Performance

Shares of KPTI opened at $0.61 on Friday. The company has a market capitalization of $76.98 million, a PE ratio of -0.60 and a beta of 0.06. Karyopharm Therapeutics has a one year low of $0.53 and a one year high of $1.70. The company's fifty day moving average price is $0.66 and its 200 day moving average price is $0.76.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its earnings results on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. The firm had revenue of $30.54 million during the quarter, compared to the consensus estimate of $30.29 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KPTI. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Karyopharm Therapeutics by 46.3% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company's stock valued at $4,274,000 after buying an additional 2,000,000 shares during the period. GSA Capital Partners LLP boosted its holdings in shares of Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock valued at $1,474,000 after buying an additional 792,283 shares during the period. Jane Street Group LLC boosted its holdings in shares of Karyopharm Therapeutics by 265.5% in the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock valued at $506,000 after buying an additional 543,556 shares during the period. Marshall Wace LLP boosted its holdings in shares of Karyopharm Therapeutics by 15.3% in the fourth quarter. Marshall Wace LLP now owns 2,401,413 shares of the company's stock valued at $1,633,000 after buying an additional 319,187 shares during the period. Finally, Shay Capital LLC acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at approximately $116,000. Institutional investors and hedge funds own 66.44% of the company's stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.